Timetable

Explore the Timetable to dis­cov­er the full sched­ule of oncol­o­gy-focused pre­sen­ta­tions. Here you’ll find detailed infor­ma­tion about speak­ers, lec­ture top­ics, and start times. Plan your par­tic­i­pa­tion and make sure not to miss the ses­sions that mat­ter most to you. 

May 28, Thursday
9.00 — 9.15
Offi­cial Opening 
Can­cer Biology 
9.15 — 9.45
Aurélie Poli 
Lux­em­bourg Insti­tute of Health, LUXEMBOURG 
Aller­goOn­col­o­gy: Lessons Learned from the Aller­gy-Glioblas­toma Connection 
9.45 — 10.15
Joan­na Poźniak 
KU Leu­ven, BELGIUM 
Cyto­tox­ic NK Cells Impede Response to Check­point Immunother­a­py in Melanoma with an Immune-Exclud­ed Phenotype 
10.15 — 10.45
Camille Chatelain 
Lund Uni­ver­si­ty, SWEDEN 
Induc­ing Immuno­genic Ter­tiary Lym­phoid Struc­tures Across Can­cer Types With Den­drit­ic Cell Reprogramming 
10.45 — 11.15
Tim Halim 
Can­cer Research UK Cam­bridge Insti­tute, UNIT­ED KINGDOM 
The Role of ILC2 in Tis­sue Home­osta­sis and Neoplasia 
11.15 — 11.45
Break 
Can­cer Neuroscience 
11.45 — 12.15
Andrew Shepherd 
Uni­ver­si­ty of Texas MD Ander­son Can­cer Cen­ter, USA 
Latent Neu­ropa­thy in Col­orec­tal Can­cer: Impli­ca­tions for Can­cer Survivorship 
12.15 — 12.45 
Christi­na Møller Andreasen 
Uni­ver­si­ty of South­ern Den­mark, DENMARK 
Remod­el­ling of the Bone Microen­vi­ron­ment Dur­ing Can­cer Infil­tra­tion: Insights from Mul­ti­plex Imag­ing and Spa­tial Transcriptomics 
​12.45 — 13.15
Christoph Klose 
Char­ité – Uni­ver­sitätsmedi­zin Berlin, GERMANY 
Enteric Ner­vous Sys­tem-Derived VIP Restrains Dif­fer­en­ti­a­tion of LGR5+ Stem Cells Towards the Secre­to­ry Lin­eage Imped­ing Type 2 Immune Programs 
13.15 — 14.30
Lunch Break 
Can­cer Therapy 
14.30 — 15.00
Tobias Bald 
Uni­ver­si­ty of Bonn, GERMANY 
Tar­get­ing the Dark Mat­ter of Can­cer with AI-Designed Mini Binder 
15.00 — 15.30
Hele­na Florindo 
Uni­ver­si­ty of Lis­bon, PORTUGAL 
Engi­neer­ing Nanomed­i­cines for Tar­get­ed Neu­roim­mune Modulation 
15.30 — 16.00
Gabri van der Pluijm 
Lei­den Uni­ver­si­ty Med­ical Cen­ter, THE NETHERLANDS 
Poten­ti­at­ing Immunother­a­py of Uro­log­i­cal Can­cers with Oncolyt­ic Viruses 
16.00 — 16.15
Indus­try Con­tact Point 
Łukasiewicz – PORT, POLAND 
Strate­gic Pri­or­i­ties in Can­cer Ther­a­py: Nav­i­gat­ing the 2026 Can­cer Mis­sion Calls 
16.15 — 16.30
Break 
16.30 — 17.30
KEYNOTE: Frank Winkler 
Uni­ver­sität­sklinik Hei­del­berg, GERMANY 
Can­cer Neu­ro­science of Brain Tumors 
19.00
Con­fer­ence Net­work­ing Event 
Offi­cial Dinner 
Przys­tań & Mari­na Restau­rant
Księ­cia Witol­da 2, 50 – 202 Wrocław 

May 29, Friday
Can­cer Therapy 
9.00 — 9.30
Shee­ba Irshad 
King’s Col­lege Lon­don, UNIT­ED KINGDOM 
Spa­tial Repro­gram­ming of Immune Sur­veil­lance in Breast Can­cer: From Immune Con­trol to Immune Failure 
9.30 — 10.00
Ste­faan Van Gool 
IOZK Immun-Onkol­o­gis­ches Zen­trum Köln, GERMANY 
The War Against Glioblas­toma Needs More Than Stan­dard of Care 
10.00 — 10.30
Jür­gen Kuball 
Uni­ver­si­ty Med­ical Cen­ter Utrecht, THE NETHERLANDS 
Uncov­er­ing the Spa­tial Reg­u­la­tion of γδ T Cells: Toward Recep­tor-Guid­ed Immunotherapy 
10.30 — 11.00
Break 
11.00 — 11.30
Jarosław Dybko 
Low­er Sile­sian Oncol­o­gy Cen­ter in Wro­claw, POLAND 
Lat­est Advances in CAR‑T Ther­a­py in Lym­phoma: Where Are We and Where Are We Going? 
11.30 — 12.00
Sébastien Wälch­li (online)
Oslo Uni­ver­si­ty Hos­pi­tal, NORWAY 
Expand­ing CAR Tar­gets to Non Pro­tein Antigens 
12.00 — 12.30
Helen Kakkassery 
King’s Col­lege Lon­don, UNIT­ED KINGDOM 
Advanc­ing BIA-ALCL Research Through a UK – PORT Alliance — From Biobank­ing to Immune Discovery 
12.30 — 13.30
Lunch Break 
PORT for Busi­ness — Com­pa­ny Session 
13.30 — 13.40
Mal­wina Woźniak 
Łukasiewicz – PORT, POLAND 
From Sam­ple to Insight: Advanced Ana­lyt­ics for Oncol­o­gy Research 
13.40 — 13.50
Mar­iusz Olejniczak 
WPD Phar­ma­ceu­ti­cals, POLAND 
Beyond glioblas­toma — WPD Pharmaceuticals 
13.50 — 14.00
Zbig­niew Zasłona 
Mol­e­cure, POLAND 
The Devel­op­ment of USP7 Inhibitor for Can­cer Immunotherapy 
14.00 — 14.10
Mile­na Mazan 
Ryvu Ther­a­peu­tics, POLAND 
Lever­ag­ing Can­cer Biol­o­gy for Ther­a­peu­tic Inno­va­tion: Clin­i­cal and Dis­cov­ery Advances at Ryvu 
14.10 — 14.20
TBC 
Enam­ine, POLAND 
TBC 
14.20 — 14.30
Marek Kudła 
Ardi­gen, POLAND 
TBC 
14.30 — 14.40
Artur Wnorowski 
Biotech­na, POLAND 
TBC 
14.40 — 14.50
Jakub Knurek 
Mabion, POLAND 
Devel­op­ment of Bio­log­i­cal Drugs for Onco­log­i­cal Indi­ca­tions at Mabion 
14.50 — 15.00
Offi­cial Closure 

Guid­ed by a Lead­ing Sci­en­tif­ic Committee

Dis­cov­er the experts behind the con­fer­ence pro­gram. Get to know the Sci­en­tif­ic Com­mit­tee respon­si­ble for shap­ing the agen­da, ensur­ing sci­en­tif­ic excel­lence, and guid­ing every session.

Meet the Sci­en­tif­ic Committee